Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities
NCT07888114
Summary
Pediatric soft tissue sarcomas (STS) are a group of malignant tumors originating from primitive mesenchymal tissues and account for approximately 7% of childhood cancers. STS are broadly classified into rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). RMS accounts for approximately one half of pediatric STS. As reported, PAX fusion-positive RMS is more aggressive than fusion-negative RMS, with higher metastatic potential and poorer prognosis. Based on the unmet therapeutic need in pediatric sarcoma with PAX-family abnormalities, this study is intended to evaluate the preliminary safety and antitumor activity of entinostat with or without chemontherapy.
Eligibility
Inclusion Criteria: 1. Age \>1 year and ≤18 years. 2. Histologically confirmed malignant soft tissue sarcoma that is PAX3-FOXO1- or PAX7-FOXO1-fusion positive or has another PAX-family gene abnormality. 3. Clinical disease status: (a) monotherapy cohort: completion of standard backbone chemotherapy and/or radiotherapy with a favorable clinical response (CR or PR); (b) combination cohort: inadequate response following standard chemotherapy and/or radiotherapy, or recurrent/progressive disease. 4. Karnofsky Performance Status (KPS) ≥50 or Lansky Performance Status (LPS) ≥50. 5. Adequate bone marrow function: ANC ≥0.5 × 10\^9/L, platelet count ≥50 × 10\^9/L, hemoglobin ≥70 g/L, and WBC ≥1.5 × 10\^9/L, with values not exceeding the upper limit of normal. 6. Life expectancy of at least 6 months. 7. Written informed consent obtained. Exclusion Criteria: 1. Previous hematopoietic stem cell transplantation or organ transplantation. 2. Participation in another drug clinical trial within 2 months before enrollment. 3. Uncontrolled infection or body temperature ≥38°C. 4. Total bilirubin, ALT, and AST \>2.5 × the upper limit of normal. 5. Serum creatinine \>2.0 × the upper limit of normal. 6. Any other condition considered by the investigator to constitute a contraindication to study participation.
Conditions2
Interventions2
Related trials
- A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy — Zhejiang Cancer Hospital
- Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer — Hebei Medical University Fourth Hospital
- Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure — Tianjin Medical University Cancer Institute and Hospital
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors — National Cancer Institute (NCI)
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07888114